Pediatric patients infected with HCV genotypes 1, 3, 4, 5, and 6 will be treated with ledipasvir and sofosbuvir (with and without ribavirin). There will also be a placebo arm. A lead-in phase is testing the safe and effective dose. After the lead-in phase, the same patients will be treated with the combinations. There are different arms based on the ages of the children.
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/-Ribavirin in Adolescents and Children With Chronic HCV-Infection
To view the entire clinical trial description, click here